Company intelligence / Profile preview

Lux Biosciences, Inc.

Jersey City, New Jersey, USorpha.net ↗

Ownership: Private
Employees: ~2
Development stage: Phase 3

Overview

Lux Biosciences developed LUVENIQ™ (oral voclosporin) for non-infectious uveitis. The drug showed positive Phase 3 results but received a complete response letter from the FDA requiring additional trials. The European Medicines Agency review was ongoing as of early 2010s. Other pipeline assets included LX214 (topical voclosporin) for dry eye syndrome in Phase 1 and LX212 implant for severe dry eye in research stage[5]. No recent clinical results are available after these regulatory events.

Therapeutic areas: Ophthalmology
Modalities: Small molecules (notably oral and topical formulations of voclosporin)
Industry: Biotech

Drug pipeline

1 asset

LX201

Preclinical

Partnerships

Isotechnika Pharma—collaboration on development and commercialization of voclosporin-based products

Beyond the preview

Go deeper on Lux Biosciences, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lux Biosciences, Inc..

Explore the full profile